July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and sodium ioxaglate) and Optimark (gadoversetamide).

Following the acquisition of Mallinckrodt’s contrast media & delivery systems business, Guerbet has taken measures to streamline its brand portfolio.

IBA (Ion Beam Applications S.A.) and Inova recently signed a contract for a two-room Proteus Plus proton therapy solution, each treatment room equipped with pencil beam scanning capability and integrated cone beam computed tomography (CBCT). Inova plans to start treating patients by 2020 at the Inova Schar Cancer Institute on the Inova Center for Personalized Health campus in Annandale, Va.

National Decision Support Company announced the full qualification of its CareSelect Platform as a Qualified Clinical Decision Support Mechanism (qCDSM) by the Centers for Medicare and Medicaid Services (CMS). The qualification indicates compliance with the Appropriate Use Criteria (AUC) provisions under the Protecting Access to Medicare Act (PAMA) and the Medicare Access and CHIP Reauthorization Act (MACRA).

Last-minute defections from two Republican senators early Tuesday ensured the chamber’s version of the Better Care Reconciliation Act (BCRA) would not have enough votes to secure passage. President Trump and GOP leadership indicated that despite this latest defeat, they would continue to work on legislation to repeal and replace the Affordable Care Act (ACA), popularly known as ObamaCare.

Radiologists from Synergy Radiology Associates (SRA) in Houston are using the power of 3-D medical imaging and subspecialty radiology to provide better patient care for men with suspicious prostate cancer findings.

Proton International (PI) and Beaumont Health recently opened the state’s first proton therapy center, offering the most advanced form of radiation treatment available to people with a wide range of cancers.

Ionizing radiation, such as X-rays, has a harmful effect on the cardiovascular system even at doses equivalent to recurrent computed tomography (CT) imaging, a new study published in the International Journal of Radiation Biology suggests.

The American Society for Radiation Oncology (ASTRO) has issued an update to its recommendations for medical insurance coverage regarding the use of proton beam therapy to treat cancer. The updated Proton Beam Therapy Model Policy provides guidance to payers on clinical indications that are appropriate for treatment with proton therapy and should be covered by health insurance, including Medicare, Medicaid and private insurance.

The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of contrast media.

July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET) radiotracer that is widely used to diagnose hypoxia and non-small cell lung cancer (NSCLC) patients with FMISO uptake are known to face a poor prognosis.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now